MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.Cancer immunology research · 2014
   Trial
2. IncreasedPharmaceuticals (Basel, Switzerland) · 2024
   Article
3. Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.Oncology letters · 2017
   Article
4. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.Current hematologic malignancy reports · 2015
   Review
5. Immunotherapy strategies for multiple myeloma: the present and the future.Immunotherapy · 2013
   Review
6. MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients.Leukemia · 2013
   Article
7. Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.Virchows Archiv : an international journal of pathology · 2013
   Article
8. Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.PloS one · 2013
   Article
9. Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.Clinical & developmental immunology · 2012
   Review
10. Immunogenic targets for specific immunotherapy in multiple myeloma.Clinical & developmental immunology · 2012
    Review
11. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.Cancer immunology, immunotherapy : CII · 2011
    Article
12. Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.Cancer immunity · 2011
    Article
13. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.PloS one · 2011
    Article
14. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.Proceedings of the National Academy of Sciences of the United States of America · 2010
    Article
15. A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.Cancer immunity · 2010
    Article
16. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.Haematologica · 2010
    Article
17. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.Cancer immunity · 2010
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

14 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as